# US 2021/0171552 A1 · Phosphoantigen prodrug compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171552 A1
- Document ID: US20210171552A1
- Status: Published application
- Kind: A1
- Application number: 17/256,272
- Filed: 2019-07-03
- Published: 2021-06-10
- Earliest claimed: 2018-07-04
- Assignees: University College Cardiff Consultants Limited; The University of Birmingham
- Applicants: University College Cardiff Consultants Ltd; University of Birmingham
- Inventors: Youcef Mehellou; Benjamin Willcox
- Web page: https://patentgrep.com/patent/US20210171552A1

## CPC

- A61K 31/664: Amides of phosphorus acids
- C07F 9/4465: {of aliphatic amines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/42: Cancer antigens
- A61P 19/00: Drugs for skeletal disorders
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- C12N 5/0636: {T lymphocytes}
- C12N 2501/999: Small molecules not provided for elsewhere
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a compound of General Formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein. Compounds and compositions comprising the same exhibit high serum stability and potent activation of the γδ T-cell immune response, so are suitable for use in immunotherapy. The invention also relates to methods of immunotherapy using the compounds of General Formula (I).

## Claims

### Claim 1

A compound according to General Formula (I) including all tautomers thereof:
wherein R1 and R2 each independently represents an amino acid ester radical according to General Formula (II) or an aryloxy radical according to General Formula (III):
wherein R6 represents H, or a saturated or unsaturated and optionally substituted hydrocarbon chain;
R7 represents a saturated or unsaturated and optionally substituted hydrocarbon chain; and
R8 represents an optionally substituted C5-25 aryl or a 5 to 25 membered heteroaryl group;
R3 represents an optionally substituted C2-20 alkyl, C4-20 alkenyl or C2-20 alcohol radical; and
each of R4 and R5 independently represent H or halo;
or a salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein said compound is of General Formula (IV), wherein R3, R4, R5, R6, R7 and R8 are as defined in claim 1:

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R3 is a radical according to Formula (V), Formula (VI) or Formula (VII), wherein R9 is selected from OH, OR10, SH, SR10, NH2 or NHR10, and wherein R10 represents C1-4 alkyl:

### Claim 4 (depends on 3)

A compound according to claim 3, wherein R9 is OH.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein one or both, of R4 and R5 represent halo.

### Claim 6 (depends on 5)

A compound according to claim 5, wherein said halo substituents is/are fluoro.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein R6 is a C1-4 alkyl chain.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein R7 is an unsubstituted C1-4 alkyl chain or an unsubstituted benzyl group.

### Claim 9 (depends on 1)

A compound according to claim 1, selected from:

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable excipient or carrier.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A method of immunotherapy, the method comprising administering to a subject an effective amount of a compound as defined in claim 1 to activate a γδ T-cell immune response.

### Claim 15 (depends on 14)

A method according to claim 14, wherein said compound is administered ex vivo to a sample obtained from an individual in need of treatment to induce proliferation of γδ T cells prior to said sample being returned to the body.

### Claim 16 (depends on 14)

A method according to claim 14, wherein said compound is administered to treat an infection, a proliferative disease or osteoporosis.

### Claim 17 (depends on 16)

A method according to claim 16, wherein said proliferative disease is a cancer.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 10)

A method of immunotherapy, the method comprising administering to a subject an effective amount of a pharmaceutical composition as defined in claim 10 to activate a γδ T-cell immune response.

### Claim 22 (depends on 21)

A method according to claim 21, wherein said composition is administered to treat an infection, a proliferative disease or osteoporosis.

### Claim 23 (depends on 22)

A method according to claim 22, wherein said proliferative disease is a cancer.

### Claim 24 (depends on 21)

A method according to claim 21, wherein said composition is administered ex vivo to a sample obtained from an individual in need of treatment to induce proliferation of γδ T cells prior to said sample being returned to the body.

### Claim 25 (depends on 24)

A method according to claim 24, wherein said composition is administered to treat an infection, a proliferative disease or osteoporosis.

### Claim 26 (depends on 25)

A method according to claim 25, wherein said proliferative disease is a cancer.

### Claim 27 (depends on 15)

A method according to claim 15, wherein said compound or composition is administered to treat an infection, a proliferative disease or osteoporosis.

### Claim 28 (depends on 27)

A method according to claim 27, wherein said proliferative disease is a cancer.
